• 1
    Kaplan HS. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology. 1962; 78: 553-561.
  • 2
    Devita VT Jr, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970; 73: 881-895.
  • 3
    Tubiana M, Henry-Amar M, Hayat M, Breur K, van der Werf-Messing B, Burgers M. Long-term results of the EORTC randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. Eur J Cancer. 1979; 15: 645-657.
  • 4
    Andrieu JM, Montagnon B, Asselain B, et al. Chemotherapy-radiotherapy association in Hodgkin's disease, clinical stages IA, II2A: results of a prospective clinical trial with 166 patients. Cancer. 1980; 46: 2126-2130.
  • 5
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975; 36: 252-259.
  • 6
    Valagussa P, Santoro A, Kenda R, et al. Second malignancies in Hodgkin's disease: a complication of certain forms of treatment. BMJ. 1980; 280: 216-219.
  • 7
    Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol. 1996; 14: 1928-1935.
  • 8
    le Maignan C, Desablens B, Delwail V, et al. Three cycles of Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004; 103: 58-66.
  • 9
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 1860-1861.
  • 10
    Armitage P. Attitudes in clinical trials. Stat Med. 1998; 17: 3675-3683.
  • 11
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009; 62: 499-505.
  • 12
    Schwartz D, Flamant R, Lellouch J. l'Essai Therapeutique chez l'Homme. 2nd ed. Paris, France: Flammarion Medecine Sciences; 1981.
  • 13
    Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006; 24: 3128-3135.
  • 14
    Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007; 25: 3495-3502.
  • 15
    Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 4634-4642.
  • 16
    Macdonald DA, Connors JM. New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2007; 21: 871-880.
  • 17
    Bar Ad V, Paltiel O, Glatstein E. Radiotherapy for early-stage Hodgkin's lymphoma: a 21st century perspective and review of multiple randomized clinical trials. Int J Radiat Oncol Biol Phys. 2008; 72: 1472-1479.
  • 18
    Rehan F, Brilliant C, Schiltz H, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma [abstract]. Blood. 2007; 110: 686a. Abstract 2320.
  • 19
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004; 15: 2835-2841.
  • 20
    Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ. 1992; 304: 1137-1143.
  • 21
    Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995; 1: 33-42.
  • 22
    Henry-Amar M, Joly F. Late complications after Hodgkin's disease. Ann Oncol. 1996; 7( suppl 4): 115-126.
  • 23
    Yahalom JH. Role of radiation therapy in Hodgkin's lymphoma. Cancer J. 2009; 15: 155-160.
  • 24
    Radford J. Limited-stage disease: optimal use of chemotherapy and radiation treatment. Hematology Am Soc Hematol Educ Program. 2008; 321-325.
  • 25
    Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002; 20: 2101-2108.
  • 26
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002; 20: 3484-3494.
  • 27
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003; 21: 3431-3439.
  • 28
    Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev. 2005; 4: CD003187.
  • 29
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993; 270: 1949-1955.
  • 30
    Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol. 2006; 24: 605-611.
  • 31
    Vijayakumar S, Myrianthopoulos LC. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol. 1992; 24: 1-13.
  • 32
    Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL) [abstract]. J Clin Oncol. 2005; 23: 561s. Abstract 6505.
  • 33
    Diehl V, Brillant A, Engert R, et al. HD10: investigating reduction of combined modality treatment intensity in early stage Hodgkin lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) [abstract]. J Clin Oncol. 2005; 23: 561s. Abstract 6506.
  • 34
    Weihrauch MR, Re D, Scheidhauer K, Anse S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001; 98: 2930-2934.
  • 35
    Friedberg JW, Fischman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004; 45: 85-92.
  • 36
    Rigacci L, Castagnoli A, Dini C, et al. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep. 2005; 14: 1209-1214.
  • 37
    Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am. 2008; 46: 225-241.
  • 38
    Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after 2 or 3 cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005; 16: 1160-1168.
  • 39
    Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009; 27: 1906-1914.